VERTEX PHARMACEUTICALS INC / MA
VRTXNasdaqGSLatest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Miss Consensus
Reported EPS of $4.73 per share fell below the same-quarter consensus EPS of $4.75 per share for the period ended 2026-06-30.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $3.33bn, up 12.45% from $2.96bn for the quarter ended 2025-06-30.
CF Segment Dominance
Cystic Fibrosis Products revenue of $32.08bn was 96.2% of consolidated revenue for the period ended 2026-06-30, up 10.6% from $29.02bn in 2025-06-30.
Collaborative Revenue Surge
Collaborative and Royalty revenue of $8.21bn was 24.6% of consolidated revenue for the period ended 2026-06-30, up 3,867.1% from $207.0m in 2025-06-30.
Gross Margin Narrowing
Gross margin for the quarter ended 2026-06-30 was 85.33%, narrower than the 86.25% recorded for the quarter ended 2025-06-30.
Cash Flow Coverage
Filed free cash flow of $3.194B was 1.58x common-stock repurchases of $2.017B in 2025-12-31.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for VRTX
Revenue segmentation
Loading segment disclosures…